Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de...
Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial
About this item
Full title
Author / Creator
Övriga starka forskningsmiljöer , LUCC: Lund University Cancer Centre , Biomarkers and epidemiology , Biomarkörer och Epi , Section I , Breast cancer treatment , Personalized Breast Cancer Treatment , Department of Clinical Sciences, Lund , Lund University , Breast/ovarian cancer , Profile areas and other strong research environments , Breast and Ovarian Cancer Genomics , Faculty of Medicine , Medicinska fakulteten , Other Strong Research Environments , Bröst- och ovarialcancer , Individuell Bröstcancerbehandling , Breast cancer Proteogenomics , Institutionen för kliniska vetenskaper, Lund , Lunds universitet , Sektion I , Profilområden och andra starka forskningsmiljöer , Bröst/ovarialcancer , Bröstcancer Proteogenomik , Bröstcancerbehandling , LUCC: Lunds universitets cancercentrum , Stenmark Tullberg, Axel , Sjöström, Martin , Tran, Lena , Niméus, Emma , Killander, Fredrika , Kovács, Anikó , Lundstedt, Dan , Holmberg, Erik and Karlsson, Per
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundThe implementation of immunological biomarkers for radiotherapy (RT) individualization in breast cancer requires consideration of tumor-intrinsic factors. This study aimed to investigate whether the integration of histological grade, tumor-infiltrating lymphocytes (TILs), programmed cell death protein-1 (PD-1), and programmed death ligand...
Alternative Titles
Full title
Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial
Authors, Artists and Contributors
Author / Creator
LUCC: Lund University Cancer Centre
Biomarkers and epidemiology
Biomarkörer och Epi
Section I
Breast cancer treatment
Personalized Breast Cancer Treatment
Department of Clinical Sciences, Lund
Lund University
Breast/ovarian cancer
Profile areas and other strong research environments
Breast and Ovarian Cancer Genomics
Faculty of Medicine
Medicinska fakulteten
Other Strong Research Environments
Bröst- och ovarialcancer
Individuell Bröstcancerbehandling
Breast cancer Proteogenomics
Institutionen för kliniska vetenskaper, Lund
Lunds universitet
Sektion I
Profilområden och andra starka forskningsmiljöer
Bröst/ovarialcancer
Bröstcancer Proteogenomik
Bröstcancerbehandling
LUCC: Lunds universitets cancercentrum
Stenmark Tullberg, Axel
Sjöström, Martin
Tran, Lena
Niméus, Emma
Killander, Fredrika
Kovács, Anikó
Lundstedt, Dan
Holmberg, Erik
Karlsson, Per
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0736d5bb3c344d828645d3fe5bef9cfb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0736d5bb3c344d828645d3fe5bef9cfb
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-006618
How to access this item
ERROR: Invalid URL specified.
